Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium hydroxide; glucose monohydrate - indications as at 6 april 2004: marcain 0.5% and marcain spinal 0.5% heavy are indicated for the production of spinal anaesthesia. marcain 0.5% is suitable for lower limb surgery lasting 3 - 4 hours where muscle relaxation is desired or needed. marcain spinal 0.5% heavy is suitable for abdominal surgery lasting 45 - 60 minutes and urological and lower limb surgery lasting 2 - 3 hours.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 5.28 mg/ml) - injection, solution - excipient ingredients: sodium hydroxide; water for injections; dilute hydrochloric acid; sodium chloride - indications as at 4 april 2000: marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - adrenaline acid tartrate 1:100000; lidocaine hydrochloride 2%;   - solution for injection - 1:100000/2% in 2.2ml - active: adrenaline acid tartrate 1:100000 lidocaine hydrochloride 2%  

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - adrenaline acid tartrate 1:200000; bupivacaine hydrochloride monohydrate 0.375%;   - solution for injection - 1:200000/0.375% - active: adrenaline acid tartrate 1:200000 bupivacaine hydrochloride monohydrate 0.375%   excipient: hydrochloric acid sodium chloride sodium metabisulfite water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

astrazeneca limited - adrenaline acid tartrate 1:200000; bupivacaine hydrochloride monohydrate 0.75%;   - solution for injection - 1:200000/0.75% - active: adrenaline acid tartrate 1:200000 bupivacaine hydrochloride monohydrate 0.75%  

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 1.25 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 1.32 mg/ml); fentanyl citrate, quantity: 7.9 microgram/ml (equivalent: fentanyl, qty 5 microgram/ml) - injection, solution - excipient ingredients: sodium chloride; water for injections; hydrochloric acid; sodium hydroxide - marcain 0.125% with fentanyl is intended for post-operative or obstetric epidural analgesia.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 3.75 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 3.96 mg/ml) - injection, solution - excipient ingredients: sodium hydroxide; sodium chloride; water for injections - indications as at 4 april 2000: marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 2.5 mg/ml (equivalent: bupivacaine hydrochloride monohydrate, qty 2.64 mg/ml) - injection, solution - excipient ingredients: sodium chloride; sodium hydroxide; hydrochloric acid; water for injections - indications as at 4 april 2000: marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia - epidural block for surgery, field block (minor and major nerve blocks and infiltration). analgesia - continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. - field block (minor nerve block and infiltration). the choice of 4 strengths, 0.125%, 0.25%, 0.375% and 0.5%, makes it possible to vary the degree of motor blockade.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - bupivacaine hydrochloride, quantity: 5 mg/ml - injection, solution - excipient ingredients: hydrochloric acid; water for injections; sodium chloride; sodium hydroxide - indications as at 6 april 2004: marcain 0.5% and marcain spinal 0.5% heavy are indicated for the production of spinal anaesthesia. marcain 0.5% is suitable for lower limb surgery lasting 3 - 4 hours where muscle relaxation is desired or needed. marcain spinal 0.5% heavy is suitable for abdominal surgery lasting 45 - 60 minutes and urological and lower limb surgery lasting 2 - 3 hours.

Ireland - English - HPRA (Health Products Regulatory Authority)

aspen pharma trading limited - adrenaline tartrate; bupivacaine hydrochloride - solution for injection - 0.5%/0.55% percent volume/volume - amides; bupivacaine, combinations